EGFR and neoplasm: In summary, when disease control is the treatment goal, most experts suggest that the primary tumor location should be considered, and anti-EGFR shows better treatment outcomes in left-sided RAS/BRAF WT mCRC because1L treatment is based on current clinical evidence.